Loading company…
Xiangxue Life Sciences develops TCR-T immunotherapies for cancer and viral infections.
Founded in 2015 and based in Guangzhou, China, Xiangxue Life Sciences researches T cell receptor technology and TCR-T adoptive immunotherapy. Its work includes precision medicine, molecular testing, TCR-T cell therapy and related laboratory services. In March 2021, it raised CNY 100 million in strategic investment from Huagai Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in